Rifaximin Use in a 13-Year-Old Child
Rifaximin is not FDA-approved for children under 12 years of age for traveler's diarrhea, and not approved for those under 18 years for hepatic encephalopathy or irritable bowel syndrome with diarrhea. However, a 13-year-old falls into a gray zone where off-label use may be considered for specific indications with appropriate dosing.
FDA-Approved Age Restrictions
The FDA label explicitly states that rifaximin safety and effectiveness have not been established in pediatric patients less than 12 years of age for traveler's diarrhea (TD) or in patients less than 18 years of age for hepatic encephalopathy (HE) and IBS-D 1. At 13 years old, this patient technically meets the minimum age for TD indication only.
Clinical Context for Off-Label Use
For Recurrent Clostridioides difficile Infection (CDI)
The 2018 IDSA/SHEA guidelines address rifaximin use in pediatric CDI but with significant limitations. For second or subsequent recurrence of CDI in children, vancomycin for 10 days followed by rifaximin for 20 days is an option, BUT the guidelines explicitly state "no pediatric dosing for rifaximin; not approved by the US Food and Drug Administration for use in children <12 years of age" 2.
For a 13-year-old with recurrent CDI, the adult dosing would be rifaximin 400 mg three times daily for 20 days following vancomycin therapy (weak recommendation, very low quality of evidence) 2.
For Inflammatory Bowel Disease
Research data from pediatric IBD patients shows rifaximin has been used at doses ranging between 10-30 mg/kg/day 3. In this retrospective review of 23 pediatric IBD patients (median age 13 years), rifaximin was well-tolerated with 60% experiencing relief of diarrhea and 70.6% relief of abdominal pain within 4 weeks. Higher doses showed statistically better results for abdominal pain 3.
For Bacterial Diarrhea
Pediatric studies have used rifaximin 100 mg every 6 hours (400 mg/day total) for 3-4 days in children with bacterial enteritis 4, 5. This dosing achieved bacteriological cure rates of 87.5% with excellent tolerability 4.
For Helicobacter pylori Eradication
Research in adolescents (mean age 14.5 years) used rifaximin 800 mg/day for 10 days in combination therapy, achieving 85.4% eradication rates with no serious adverse reactions 6, 7.
Practical Dosing Approach for a 13-Year-Old
If rifaximin is being considered off-label for this 13-year-old:
For traveler's diarrhea or acute bacterial enteritis: 200 mg three times daily for 3 days (standard adult TD dosing, as patient meets minimum age requirement)
For recurrent CDI (after vancomycin): 400 mg three times daily for 20 days (adult dosing, given guideline recommendation despite lack of pediatric-specific data)
For IBD-related symptoms: 10-20 mg/kg/day divided into 2-3 doses (based on pediatric research data) 3
Critical Safety Considerations
Rifaximin has minimal systemic absorption, which contributes to its favorable safety profile 1. The drug acts locally in the gastrointestinal tract. However:
- Monitor for development of C. difficile infection, as with any antibiotic use
- Assess for severe hepatic impairment (though no dose adjustment needed, caution advised) 1
- Avoid in patients with known hypersensitivity to rifaximin, rifamycin derivatives, or any components
- Be aware of emerging resistance patterns, particularly with prolonged use 8, 9
When NOT to Use Rifaximin
- Do not use for systemic bacterial infections - rifaximin is not suitable due to limited systemic absorption 1
- Reconsider if patient has severe hepatic impairment (Child-Pugh Class C), though local action may still be beneficial 1
- Avoid if treating conditions requiring systemic antibiotic coverage
Documentation and Informed Consent
Given the off-label nature for most indications in this age group, document the specific indication, rationale for use, discussion of FDA approval status, and informed consent from parents/guardians. The decision should weigh the specific clinical scenario, severity of condition, alternative treatment options, and available evidence for the particular indication.